Gemcitabine (GEM) and Vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): A phase II study in elderly or poor performance status patients-Reference-Cited by-同舟云学术

Gemcitabine (GEM) and Vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): A phase II study in elderly or poor performance status patients

Published:2006-09 Issue:3 Volume:53 Page:355-360
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Santo Antonio,Genestreti Giovenzio,Terzi Alberto,Azzoni Paolo,Sava Teodoro,Manno Pietro,Molino Annamaria,Pattaro Cristian,Micciolo Rocco,Cetto Gian Luigi

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. The National Cancer Data Base report on lung cancer;Fry;Cancer,1996

2. Chemotherapy in non small cell lung cancer: a meta-analysis using update data on individual patients from 52 randomized clinical trials;Non Small Cell Lung Cancer Cooperative Group;Br Med J,1995

3. Under representation of patients of 65 years of age or older in cancer treatment trials;Hutchins;N Engl J Med,1999

4. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population based study;Janssen-Heijnen;Lung Cancer,1998

5. Comorbidity and functional status are independent in older patients;Extermann;J Clin Oncol,1998

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC;BioMed Research International;2014

2. HIF1α Genetic Variants and Protein Expressions Determine the Response to Platinum Based Chemotherapy and Clinical Outcome in Patients with Advanced NSCLC;Cellular Physiology and Biochemistry;2013

3. RAGE Genetic Polymorphisms Are Associated with Risk, Chemotherapy Response and Prognosis in Patients with Advanced NSCLC;PLoS ONE;2012-10-05

4. Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study;Lung Cancer;2009-01

5. An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study;Critical Reviews in Oncology/Hematology;2007-10